Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial
2016 ASTRO Annual MeetingAnders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventionally fractionated radiotherapy for intermediate-risk prostate cancer. (Abstract LBA-5)
Related Videos
Meena Moran, MD, on Ductal Carcinoma In Situ: Improving Local Control
Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local contr...
Maria Werner-Wasik, MD, on Issues in Lung Toxicity
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation ...
Douglas W. Arthur, MD, on Breast-Preserving Surgery: Results From NRG Oncology/RTOG 1014
Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial bre...
Lia M. Halasz, MD, on Disparities in Radiotherapy Delivery
Lia M. Halasz, MD, of the University of Washington Seattle Cancer Care Alliance, summarizes a session on the uneven delivery of radiotherapy in the United States and around the world....
Bruce D. Minsky, MD's, Meeting Highlights: An Expert Perspective
Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.
